

Naji Tabet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9397735/publications.pdf>

Version: 2024-02-01

70
papers

3,434
citations

270111

25
h-index

182931

54
g-index

72
all docs

72
docs citations

72
times ranked

5550
citing authors

#	ARTICLE	IF	CITATIONS
1	Night-to-night variation in sleep associates with day-to-day variation in vigilance, cognition, memory, and behavioral problems in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	6
2	Prospective Memory: Age related change is influenced by APOE genotype. <i>Aging, Neuropsychology, and Cognition</i> , 2020, 27, 710-728.	0.7	3
3	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 164.	4.5	113
4	Are symptoms of insomnia in primary care associated with subsequent onset of dementia? A matched retrospective case-control study. <i>Aging and Mental Health</i> , 2020, 24, 1466-1471.	1.5	6
5	Mid age APOE ϵ 4 carriers show memory-related functional differences and disrupted structure-function relationships in ϵ 4 hippocampal regions. <i>Scientific Reports</i> , 2020, 10, 3110.	1.6	15
6	Minocycline 200%mg or 400%mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-62.	0.9	10
7	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. <i>The Cochrane Library</i> , 2019, 2019, CD011906.	1.5	77
8	Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. <i>The Cochrane Library</i> , 2019, 2019, CD011905.	1.5	78
9	Using event-related fMRI to examine sustained attention processes and effects of APOE ϵ 4 in young adults. <i>PLoS ONE</i> , 2018, 13, e0198312.	1.1	4
10	The Elusive Nature of ϵ 4 APOE in Mid-adulthood: Understanding the Cognitive Profile. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 239-253.	1.2	24
11	Changes of renin-angiotensin system-related aminopeptidases in early stage Alzheimer's disease. <i>Experimental Gerontology</i> , 2017, 89, 1-7.	1.2	13
12	Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2017, 1, CD002854.		63
13	Disrupted neural activity patterns to novelty and effort in young adult ϵ 4 carriers performing a subsequent memory task. <i>Brain and Behavior</i> , 2017, 7, e00612.	1.0	14
14	Vitamin E for Alzheimer's dementia and mild cognitive impairment. <i>The Cochrane Library</i> , 2017, 4, CD002854.	1.5	176
15	Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 725-733.	1.2	140
16	Is Sleep Disruption a Risk Factor for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 993-1002.	1.2	43
17	Homocysteine concentrations in the cognitive progression of Alzheimer's disease. <i>Experimental Gerontology</i> , 2017, 99, 146-150.	1.2	36
18	Herpes simplex encephalitis and Alzheimer's disease: Is there a link?. <i>Journal of the Neurological Sciences</i> , 2017, 380, 20-21.	0.3	18

#	ARTICLE	IF	CITATIONS
19	Putting attention in the spotlight: The influence of APOE genotype on visual search in mid adulthood. Behavioural Brain Research, 2017, 334, 97-104.	1.2	12
20	Knowledge and attitudes towards dementia in adolescent students. Journal of Mental Health, 2017, 26, 419-425.	1.0	24
21	Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOEε4 carriers compared with non-APOEε4 carriers. NMR in Biomedicine, 2016, 29, 614-624.	1.6	42
22	Long-Term High-Effort Endurance Exercise in Older Adults: Diminishing Returns for Cognitive and Brain Aging. Journal of Aging and Physical Activity, 2016, 24, 659-675.	0.5	9
23	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology, 2016, 87, 1045-1051.	1.5	14
24	The APOE paradox: do attentional control differences in mid-adulthood reflect risk of late-life cognitive decline. Neurobiology of Aging, 2016, 48, 114-121.	1.5	11
25	Microbes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 979-984.	1.2	426
26	The relationship between habitual physical activity status and executive function in individuals with Alzheimer's disease: a longitudinal, cross-lagged panel analysis. Aging, Neuropsychology, and Cognition, 2016, 23, 234-252.	0.7	15
27	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life. The Cochrane Library, 2015, , .	1.5	7
28	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life. The Cochrane Library, 2015, , .	1.5	9
29	Authors' reply. British Journal of Psychiatry, 2015, 207, 364-365.	1.7	0
30	Slowing the progression of Alzheimer's disease; what works?. Ageing Research Reviews, 2015, 23, 193-209.	5.0	71
31	Clinical usefulness of dopamine transporter SPECT imaging with ¹²³ I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. British Journal of Psychiatry, 2015, 206, 145-152.	1.7	52
32	Habitual physical activity (HPA) as a factor in sustained executive function in Alzheimer-type dementia: A cohort study. Archives of Gerontology and Geriatrics, 2014, 59, 91-97.	1.4	12
33	The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. International Psychogeriatrics, 2014, 26, 9-18.	0.6	158
34	Cognitive and neural signatures of the APOE E4 allele in mid-aged adults. Neurobiology of Aging, 2014, 35, 1615-1623.	1.5	71
35	Hypertension and Inflammation in Alzheimer's Disease: Close Partners in Disease Development and Progression!. Journal of Alzheimer's Disease, 2014, 41, 331-343.	1.2	45
36	Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 253-258.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 1312-1317.	1.3	16
38	MRI of carriers of the apolipoprotein E e4 allele—evidence for structural differences in normal-appearing brain tissue in e4+ relative to e4— young adults. <i>NMR in Biomedicine</i> , 2013, 26, 674-682.	1.6	22
39	Antihypertensives, angiotensin, glucose and Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 477-482.	1.4	9
40	Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status. <i>Journal of Psychopharmacology</i> , 2013, 27, 1007-1014.	2.0	8
41	APOE E4 Carriers Show Prospective Memory Enhancement Under Nicotine, and Evidence for Specialisation Within Medial BA10. <i>Neuropsychopharmacology</i> , 2013, 38, 655-663.	2.8	19
42	Prospective memory in Alzheimer-type dementia: Exploring prospective memory performance in an age-stratified sample. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 983-992.	0.8	11
43	Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer's Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls. <i>Current Alzheimer Research</i> , 2012, 9, 1069-1076.	0.7	12
44	Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2599-2611.	1.5	22
45	Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2012, 11, CD002854.		110
46	Antioxidant Enzymatic Activities in Alzheimer's Disease: The Relationship to Acetylcholinesterase Inhibitors. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 467-474.	1.2	31
47	Plasma Fetuin-A is Associated with the Severity of Cognitive Impairment in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 327-333.	1.2	31
48	Homocysteine in Alzheimer's disease: role of dietary folate, vitamin B6 and B12. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 876-877.	1.3	8
49	Vitamin and herbal extracts use in patients diagnosed with dementia: What do health professionals know and think?. <i>Aging and Mental Health</i> , 2011, 15, 267-271.	1.5	6
50	Diabetic Peripheral Microvascular Complications: Relationship to Cognitive Function. <i>Cardiovascular Psychiatry and Neurology</i> , 2011, 2011, 1-7.	0.8	15
51	Positive Effects of Cholinergic Stimulation Favor Young APOE E4 Carriers. <i>Neuropsychopharmacology</i> , 2010, 35, 1090-1096.	2.8	79
52	Non-pharmacological interventions in the prevention of delirium. <i>Age and Ageing</i> , 2009, 38, 374-379.	0.7	39
53	Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, , CD002854.		94
54	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	4.9	598

#	ARTICLE	IF	CITATIONS
55	Male gender influences response to an educational package for delirium prevention among older people: a stratified analysis. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 493-497.	1.3	8
56	Prevention, diagnosis and treatment of delirium: staff educational approaches. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 741-751.	1.4	9
57	Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. <i>International Psychogeriatrics</i> , 2005, 17, 91-98.	0.6	9
58	An educational intervention can prevent delirium on acute medical wards. <i>Age and Ageing</i> , 2005, 34, 152-156.	0.7	167
59	Obesity in middle age and future risk of dementia: Dietary fat and sugar may hold the clue. <i>BMJ: British Medical Journal</i> , 2005, 331, 454.3-455.	2.4	3
60	Alpha lipoic acid for dementia. <i>The Cochrane Library</i> , 2004, , CD004244.	1.5	9
61	In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and in Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 46-51.	0.7	8
62	Acetyl-L-carnitine for dementia. <i>The Cochrane Library</i> , 2003, , CD003158.	1.5	42
63	Ibuprofen for Alzheimer's disease. <i>The Cochrane Library</i> , 2003, , CD004031.	1.5	28
64	Endogenous Antioxidant Activities in Relation to Concurrent Vitamins A, C, and E Intake in Dementia. <i>International Psychogeriatrics</i> , 2002, 14, 7-15.	0.6	20
65	Indomethacin for Alzheimer's disease. <i>The Cochrane Library</i> , 2002, , CD003673.	1.5	36
66	Meige's syndrome in dementia with Lewy bodies. <i>Journal of the Royal Society of Medicine</i> , 2002, 95, 201-202.	1.1	2
67	Vitamins, Trace Elements, and Antioxidant Status in Dementia Disorders. <i>International Psychogeriatrics</i> , 2001, 13, 265-275.	0.6	29
68	To tell or not to tell? comparison of older patients' reaction to their diagnosis of dementia and depression. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 879-885.	1.3	97
69	Dietary and endogenous antioxidants in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 639-641.	1.3	3
70	Vitamin and mineral supplementation for prevention of dementia or delaying cognitive decline in people with mild cognitive impairment. <i>The Cochrane Library</i> , 0, , .	1.5	10